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Supervisor:  Dionicio R. Siegel 
 
Total syntheses of the neuroregenerative natural products vinaxanthone and 
xanthofulvin have been accomplished.  The synthetic routes to both molecules utilize a 
highly regioselective furan Diels-Alder cycloaddition - aromatization sequence to furnish 
the catechol fragment present in both natural products. The pentasubstituted catechol was 
elaborated to a vinylogous amide which was used twice in both syntheses, exploiting the 
pseudosymmetry found in vinaxanthone and xanthofulvin.  This approach enabled the 
dimerization of 5,6-dehydropolivione forming vinaxanthone, lending significant evidence 
to a non-enzymatically driven formation of vinaxanthone in Nature.  The total synthesis 
of vinaxanthone was accomplished in nine steps, the shortest synthesis to date, and an 
additional route was devised to access a set of analogs for biological study.  The first total 
synthesis of xanthofulvin was accomplished in 18 steps and the convergent nature of the 
synthetic plan allows for analog synthesis.  The sets of vinaxanthone and xanthofulvin 
analogs will be used to examine their inhibition of Semaphorin3A, a protein which 
inhibits neuronal regeneration, and is the biological target for both molecules.
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Chapter 1   
 
Vinaxanthone and Xanthofulvin, Xanthones and Chromones, Semaphorin3A and 
Spinal Cord Injury. 
 
The natural product vinaxanthone (1) was discovered in a Penicillium vinaceum 
(Gilman and Abbott NR6815) strain by scientists at Roche and the University of Tokyo 
as part of a screening program for phospholipase C inhibitors in 1991.1  In 2003, 
Sumitomo Pharmaceuticals disclosed the isolation of vinaxanthone (1) along with a new 
molecule, xanthofulvin (2) (also known as SM-216289), from the fungal culture 
Penicillium sp. SPF-3059 as part of a broad research program for inhibitors of 
semaphorin3A (Sema3A), an inhibitor of spinal cord regeneration.2  The Penicillium 
vinaceum fermentation produced 30 mg/L of vinaxanthone (1), and the Penicillium SPF-
3059 fermentation produced 11 mg/L of vinaxanthone (1) and 21 mg/L of xanthofulvin 
(2).  Currently there is no advance in the fermentative production of either molecule 
(Figure 1).   
 
 
 
Figure 1.  Structures of  vinaxanthone (1) and xanthofulvin (2).  
 Structurally, these natural products possess both a xanthone and chromone core 
which is novel.  Xanthones are produced from fungi, bacteria, and symbiotic composite 
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organisms – lichens.  The structural motif, xanthone (9H-xanthen-9-one) is from the 
Greek word xanthos, meaning yellow (Figure 2).   
 
 
Figure 2.  Xanthone and chromanone units. 
This superfamily of compounds has found wide application in medicinal chemistry with 
broad biological activity and the number of xanthones known approximates 1,600 
compounds.3  The xanthone compounds can be divided into subclasses based on 
monomeric or dimeric structure and degrees of saturation.  Vinaxanthone and 
xanthofulvin are considered to be heterodimers (Figure 3). 
 
 
 
 
 
Figure 3.  Xanthone subtypes. 
There has been a long-standing interest in the biosynthesis and total synthesis of 
these molecules, and representative targets 3-7 are shown (Figure 4).4-12   
 
 
 
 
 
 
 
Figure 4.  Xanthone molecules pursued in total synthesis. 
O
O
O
O
xanthone chromone
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In fungi, xanthones are synthesized in a head-to-tail assembly of eight acetate units into a 
polyacetate 8 which cyclizes to form an anthraquinone 9 which is oxidatively cleaved to 
10 (Figure 5).13-16  
 
 
 
Figure 5.  Xanthone biosynthesis in fungi. 
Phenol 10 can then form xanthone 12 through a direct pathway or through a 
dihydroxanthone intermediate 11.  This sequence of events is organism dependant in 
fungi (Figure 6).   
 
 
 
 
 
Figure 6.  Divergent xanthone formation in fungi. 
In plants, the biosynthesis of xanthones is from a mixed sequence of events.  A shikimate 
pathway forms a hydroxybenzoic acid derivative which is coupled to a triacetate 
fragment, which forms the hybrid aromatic-polyacetate 13.17-23  Aromatization furnishes 
14, which can freely rotate around the aryl-ketone bond.  This species can then undergo 
oxidative coupling to give xanthones 15 and 16.  It is known that this process can be 
catalyzed by xanthone cyclase (Figure 7).24   
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Figure 7.  Xanthone biosynthesis in plants. 
Diversity in xanthone synthesis can be also be illustrated in the oxidative modification of 
emodin 3, where two different biosynthetic pathways are operative in a single fungal 
organism.24  Through this pathway emodin 3 be oxidized to benzophenones 17 and 18 
proceeding through a series of steps to blennolides A 19 and C 5 (Figure 8).  
 
 
 
 
 
 
Figure 8.  Emodin modification to blennolides A (19) and C (5). 
 Chromones are found in nature exhibiting various biological activity.25-27  They 
have been shown to demonstrate monoamine oxidase (MAO) inhibition, anti-HIV 
activity, p38 MAP kinase inhibition, and anti-aromatase activity in the treatment of breast 
cancer.28-31  Chromone (4H-1-benzopyran-4-one) and representative chromone natural 
products are shown 20-22 (Figure 9).   
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Figure 9.  Chromone and chromone-based natural products. 
Recent work on the biosynthesis of chromone compounds has been studied by 
both Abe and Zeeck.  Abe found a plant type III polyketide synthase, pentaketide 
chromone synthase (PCS) producing pentaketide chromones (Figure 10).32   
 
 
 
Figure 10.  Pentaketide chromone synthase biosynthesis of chromones. 
In this sequence five malonyl units are condensed to a pentaketide 23 which is cyclized to 
5,7-dihydroxy-2-methylchromone 24.  Zeeck examined the biosynthesis of the 
chaetocyclinone polyketides isolated from an endosymbiotic fungus, Chaetomium sp. 
(GÖ 100/2).33  Through labeling studies a biosynthetic pathway was established and 
showed a similar heptaketide F-type folding to that found in fulvic acid (Figure 11).34,35   
 
 
 
 
Figure 11.  Biosynthetic pathway to chaetocyclinone B (30). 
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Polyketide synthase mediated folding of acetyl-CoA and six malonyl-CoA units forms 
heptaketide 25 which is cyclized to naphthol 26.  Oxidation furnished hydroxylated 
benzoquinone 27, which is further oxidized and cyclized to chromone 29 (Figure 12). 
 
 
 
 
Figure 12.  Oxidative pathway to chaetocyclinone B (30). 
 Representative fulvate-type natural products 30-33, similar to chaetocyclinone B 
and fulvic acid are shown, and all are thought to be of similar biosynthetic origin (Figure 
13).36,37   
 
 
 
Figure 13.  Fulvate-type natural products 30-33. 
While vinaxanthone (1) and xanthofulvin (2) are interesting from a structural and 
isolation standpoint, their biological profile is unique and is of significant interest.  
Vinaxanthone (1) and xanthofulvin (2) are potent inhibitors of Sema3A and have shown 
promise as small molecule therapeutics in the treatment of spinal cord injury (SCI).38 
 Semaphorins are a class of secreted or membrane-assiociated glycloproteins.  
There are more than 20 types of semaphorins categorized into eight classes on the basis 
of amino-acid sequence homology and structural features (Figure 14).39,40    
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Figure 14.  Semaphorin classes.38 
All members of the semaphorins contain a conserved Sema domain, corresponding to 
approximately 400-500 amino acids.41  Semaphorin3A is a secreted protein, structurally 
identified by Nikolov in 2003 as a 65 kDa soluble protein (Figure 15).42   
 
 
 
 
Figure 15.  Top (A) and side (B) projections of Sema3A-65K secreted protein.42  
Semaphorins act by forming a complex with their plexin receptors, which are divided into 
four classes among two types found in invertebrate species and nine in vertebrate 
species.43  Semaphorin3A, however, is unique in that it uses a neuropilin as its direct 
receptor.  Neuropilins are transmembrane glycoproteins involved in neuronal 
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development and survival.  The functional sema3A-neuropilin complex then binds with 
plexins to affect biological activity.43  Once this complex is formed the downstream 
effect is the collapse of growth cones.  This can be shown (Figure 16).44   
 
 
 
 
 
 
 
 
 
Figure 16.  Semaphorin3A –Neuropilin1-Plexin complex inducing growth cone collapse.44 
 In spinal cord injury, a series of events occurs at the wound site.  Scar tissue 
accumulates and production of sema3A is increased, inhibiting axonal regeneration.45-47  
Sema3A affects the actin cytoskeleton of neurons through microtubules in the cellular 
structure inducing growth cone collapse and chemorepulsion of new neurite outgrowth.48-
55
  It is thought that inhibiting Sema3A and subsequently preventing the inhibition of new 
neurite formation would lead to enhanced neuronal development after traumatic spinal 
cord injury. 
 In 2006 a study on the effects of xanthofulvin (2), (also known as SM-216289), 
was published by Okano.54  In this study it was found that xanthofulvin (2) inhibits the 
binding of Sema3A to neuropilin-1 (NP-1) by changing the steric structure involved in 
the association of the two proteins.  The study examined, in detail, the in vivo effects of 
intra-spinal dosing with xanthofulvin (2) in complete transection model.  The study found 
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that Sema3A accumulation was peaked 1-2 weeks post traumatic injury, corroborating a 
study which showed increased Sema3A mRNA at the lesion site in both transection and 
contusion injuries.47  This study demonstrated significant functional and cognitive 
recovery in vivo over a 14 week dosing program, pronounced gain of function in rats. 
 The effects of dosing can be seen also in in vitro models.54,55  It can be seen 
through increased dosing of xanthofulvin (2) in chick dorsal root ganglion cells that a 
direct correlation of new neurite outgrowth can be observed (Figure 17).55   
 
 
 
 
 
 
 
 
Figure 17.  Increased chick dorsal root ganglion cell outgrowth with xanthofulvin (2).55 
Similar findings were observed in the original isolation of xanthofulvin (2), with 
inhibition (IC50) of Sema3A found at 0.09 µg/mL and at 0.1 09 µg/mL for vinaxanthone 
(1).2  Importantly, the 2003 study showed no change in the cellular morphology after 
treatment with either natural product and no toxicity was observed at 1,000 times 
effective dosing.2  The Okano study showed similarly outstanding results. The use of 
 xanthofulvin (2) outperformed known inhibitors of Sema3A, lavendustin A 34 and 
olomoucine 35 (Figure 18 ).54   
10 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.  Inhibition of Sema3A in chick dorsal root ganglion cells  structures of lavendustin A 34  and olomoucine 35.54 
 The interesting structural features of these natural products coupled with their 
impressive biological profile and paucity make them outstanding candidates for total 
synthesis.  There is currently no effective treatment for spinal cord injury, and while these 
two natural products might not become treatments, they have the potential to serve as 
outstanding tools for the study of neural regeneration in this context.  Much is known 
about the process of Sema3A inhibition of neural regeneration, but a significant amount 
of progress can be made through the use of vinaxanthone (1) and xanthofulvin (2) to 
elucide more of the mechanisms involved in the anastomosis of neurons. 
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Chapter 2  
Synthesis of 5,6-Dehydropolivione and Total Synthesis of Vinaxanthone. 
 
Prior to this work, the only total synthesis of vinaxanthone (1) was disclosed by 
Tatsuta in 2007 and is discussed here.1  Retrosynthetically, vinaxanthone (1) can be 
simplified through a Diels-Alder/aromative oxidation sequence and protecting group 
transform to give enone 35 (Figure 1).   
 
 
 
Figure 19. Vinaxanthone (1) retrosynthesis. 
In the forward sense, bromination of vanillin 36 furnished aldehyde 37, which 
was methylated to furnish dimethoxy-aldehyde 38.2 Dakin oxidation of the aldehyde and 
hydrolysis of the intermediate formate furnished phenol 39 (Figure 2).3 
 
 
 
Figure 2. Synthesis of phenol 39. 
Conjugate addition of phenol 39 into acrylonitrile formed nitrile 40 which was 
hydrolyzed and cyclized under Friedel-Crafts conditions to afford chromanone 41.4 
Subsequent ketalization with ethylene glycol and TsOH formed 42 (Figure 3). 
 
 
Figure 3. Synthesis of ketal 42. 
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Ketal 42 was metallated with n-butyllithium and the resultant anion was trapped with 
methyl chloroformate to furnish, after hydrolysis of the ketal, methyl ester 43.  Vinyl 
iodide 44 was formed by treatment of 43 with iodine in hot dimethyl sulfoxide (Figure 4). 
 
 
 
Figure 4. Synthesis of iodide 44. 
Iodide 44 was then coupled with methyl vinyl ketone to furnish enone 35.5 Dimerization 
in the presence of oxygen induced aromatization to form protected vinaxanthone 45.  In 
this transformation, Tatsuta asserts that this is a biomimetic dimerization and that in 
Nature, the Diels-Alder reaction proceeds to furnish vinaxanthone (1) (Figure 5).   
 
 
 
Figure 5. Synthesis of protected vinaxanthone 45. 
The last step was to deprotect all oxygen bound methyl groups and this was accomplished 
with AlCl3 in refluxing toluene to furnish vinaxanthone (1) (Figure 6). 
 
 
 
Figure 6. Deprotection of 45 to form vinaxanthone (1). 
  While this synthesis is short and relies on a clever dimerization strategy, the 
prospect of such a Diels-Alder cycloaddition occurring in Nature is of low likelihood.6-8  
An alternative biosynthetic hypothesis for the formation of vinaxanthone (1) was reported 
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by Wrigley and involved a dimerization of two C14 polyketides to form the C28 skeleton 
of vinaxanthone through an unknown mechanism (Figure 7).9   
 
 
 
Figure 7. C14 polyketide dimerization to vinaxanthone (1). 
A proposal the biosynthesis of structurally similar fungal metabolites was put forth by 
Zeeck.10  In this proposal a heterodimerization of two C14 polyketides forms the C28 
skeleton of chaetocyclinone C (49), similar in structure to that of vinaxanthone (1) 
(Figure 8). 
 
 
 
Figure 8. Zeeck biosynthetic hypothesis to chaetocyclinone C (49). 
Interestingly there was no mention of the alternative reaction pathway where the 
speculated final aldol condensation occurs through the opposite alkene geometry in 50.  
This alternative cyclization mode is shown below (Figure 9).   
 
 
 
 
 
Figure 9. Zeeck biosynthetic hypothesis applied to xanthofulvin type connectivity 51. 
Analogously for vinaxanthone (1), Knovenagel condensation of keto-aldehyde 52 and 
5,6-dehydropolivione (53) would furnish isomeric adducts 54 and 55, differing only at 
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the enedione linkage.11  Aldol condensation would form vinaxanthone (1) and 
dehydroxanthofulvin 62, then undergoing reduction to form xanthofulvin (2) (Figure 10).  
 
 
 
 
 
 
 
 
 
 
Figure 10. Zeeck biosynthetic hypothesis applied to vinaxanthone (1) and xanthofulvin (2). 
Where both Tatsuta and Wrigley each proposed a homodimerization event of one 
monomer, Zeeck’s proposal is a heterodimerization.  However, upon further inspection of 
keto-aldehyde 52 it becomes clear that it is a rearranged form of 5,6-DHP (53).  The 
following sequence illustrates the interconversion of 5,6-DHP (53) into 52 (Figure 11).12 
 
 
 
 
Figure 11. Conversion of 5,6-DHP (54) into keto-aldehyde 53. 
Addition of water into the chromanone of 5,6-DHP (53) followed by elimination gives 
rise to 56, a highly reactive species which can cyclize in a 6-exo-dig fashion through 
attack of the proximal phenol onto the acetoacetate unit.  After elimination of water, keto-
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aldehyde 52 is formed.  This heterodimerization pathway appears plausible but the 
existence of such a keto-aldehyde 56 might be fleeting due to its highly reactive nature.   
 In the previous isolation papers and total synthesis, vinaxanthone (1), 
xanthofulvin (2), and chaetocyclinone C (49) were isolated as axially achiral species.  
The barrier to rotation around the aryl-chromone bond in vinaxanthone (1) is estimated at 
∼20 kcal/mol, precluding stable axial chirality.13  Additionally, because xanthofulvin (2) 
is co-isolated with vinaxanthone (1) it is highly suggestive of a non-enzymatically driven 
formation.  After examining the three biosynthetic hypotheses for vinaxanthone (1) and 
xanthofulvin (2) a more complete mechanistic pathway can now be outlined (Figure 12). 
 
 
 
 
 
 
Figure 12.  5,6-DHP (53) dimerization pathway to vinaxanthone (1) and xanthofulvin (2). 
Michael addition of 5,6-DHP (53) into another molecule of 5,6-DHP (53) is expected to 
furnish adduct 57.  Elimination forms enediones 58 and 59 which are in equilibrium with 
each other due to the highly delocalized nature of the tetracarbonyl system.  Chromone 
condensation of 58 or 59, both of which are in equilibrium, is expected to form 60 and 61 
which are also in equilibrium with each other (Figure 13).  
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Figure 13. Chromone condensation to vinaxanthone and xanthofulvin precursors 61 and 62. 
Cyclization of 60 and 61 forms dehydroxanthofulvin 62 and vinaxanthone (1), 
respectively (Figure 14).   
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Vinaxanthone (1) and xanthofulvin (2) from cyclization precursors. 
It is of note that the final cyclization step is speculated in the literature to be an aldol 
reaction.  The pKa of the ketonic protons in 60 and 61 are low, estimated to be 3-4 and at 
physiologic pH it is likely that 60 and 61 exist in their trienol forms 63 and 64.  If both 
O Me O
O CO2H
OH
OH
O
OHO2C
HO
HO O
O O
Me
O
Me
O
OHO2C
HO
HO O
O O
Me
O
O
HO2C
OH
OH
58 59
O
OHO2C
HO
HO
O Me
O
O
HO2C
OH
OH
O
Me
O
O
OHO2C
HO
HO
O Me
O
O CO2H
OH
OHO
O
Me
chromone condensation-H2O chromone condensation-H2O
60 61
22 
 
molecules exist as their trienol forms then the likelihood of an aldol cyclization is low 
and the reaction can be more likely to occur through a 6pi electrocyclization (Figure 
15).14,15   
 
 
 
Figure 15. Trienol 6pi electrocyclization substrates 63 and 64. 
Based upon our hypothesis for the non-enzymatic formation of vinaxanthone (1) 
in Nature, a concise synthesis for the putative monomer, 5,6-dehydropolivione (5,6-DHP) 
(53) was devised.  Retrosynthetically, 5,6-DHP (53) can be simplified through a 
protecting group transform and deacetoacylation to pentasubstituted phenol 65 (Figure 
16).   
 
 
Figure 16. 5,6-DHP (53) retrosynthesis. 
Phenol 65 is traced back to bicycle 66 which in the forward sense is the product of 
a furan Diels-Alder reaction between furan 67 and keto-ester 68.  Initial experiments into 
the reactivity of functionalized 2-siloxyfurans quickly demonstrated the requirement for 
an electron withdrawing substituent at the 4-position. Furans 69 - 72 were found to be 
unstable, decomposing rapidly and gave low yields of adducts in early studies (Figure 
17). 
 
23 
 
 
 
 
Figure 17. Furans 69 - 72 examined in the key Diels-Alder reaction. 
The use of the pivaloyl group, however, imparted not only enhanced stability but a 
significant improvement in yield of the Diels-Alder adduct.  The synthesis of furan 72 is 
shown below and has been used to routinely deliver 100 g batches of product without the 
need for purification.16  Acylation of tetronic acid 73 with pivaloyl chloride in the 
presence of catalytic 4-N,N-dimethylaminopyridine (DMAP) furnished crystalline,  
bench-stable pivaloyl tetronate 74 which was then silylated using tert-butyldimethylsilyl 
triflate in the presence of triethylamine to provide furan 72 (Figure 18).17 
 
 
Figure 18. Synthesis of furan 72. 
The synthesis of keto-ester 68 was accomplished in one of two ways.  A short route (two-
steps) employing a silver acetylide was initially used but was not scalable and required 
multiple reactions run in parallel to furnish sufficient quantities of keto-ester 68 (Figure 
19).18,19  
 
 
 
Figure 19. Synthesis of keto-ester 68. 
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A second route was found to be eminently scalable (200 g scale) and despite being four 
steps long instead of two, was a more attractive option as the intermediates were also 
bench stable for storage.  The latter route to keto-ester 68 is shown (Figure 20).20 
 
 
 
 
 
Figure 20. Scalable synthesis of keto-ester 69. 
Protection of commercially available 3-butyn-2-ol 75 as its ethoxyethyl ether 76, 
followed by metallation and trapping with di-tertbutyldicarbonate furnished 77 in nearly 
quantitative yield.  After removal of the ethoxyethyl group and oxidation of the resultant 
carbinol 78, keto-ester 68 was obtained as a pale yellow oil. 
 With significant quantities of both the diene and dienophile available the Diels-
Alder reaction between furan 72 and keto-ester 68 was now investigated.  While 
appearing straightforward, the Diels-Alder reaction between furans and unsymmetrical 
alkynoates is largely underreported.21,22 In this case there are two possible regioisomeric 
outcomes of the cycloaddition (Figure 21). 
 
 
 
Figure 21. Diels-Alder cycloadducts 79 and 80. 
The desired adduct 79 arises from the most nucleophilic carbon of the furan attacking 
keto-ester 68 at the carbon distal to the ketone functionality, the most electrophilic 
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carbon.  Mechanistically, this outcome is thought to be the most likely as the ketone is 
more electron withdrawing than the ester functionality and would exert a greater directing 
ability.  The undesired adduct 80 would arise from the alternative mechanistic pathway 
where the ester functionality exerts a greater directing ability than the ketone (Figure 22).   
 
 
 
 
 
 
Figure 22. Diels-Alder adduct rationale. 
 It was anticipated that the ketone, being a stronger electron withdrawing 
substituent compared to the ester would influence the regioselection in concert with the 
polarization of the furan.  Similar transformations are reported as intramolecular and are 
influenced by the use of a tether.  A closely related transformation was reported by 
LeCoq using an unsymmetrical aldyhyde-ester alkyne, with regioselection governed by 
the ester and not the aldehyde.23  This straightforward transformation now appeared to be 
less predictable that one would expect.  Literature precedent exists for such 
transformations using symmetrical dienophiles such as DMAD.24,25  Similar 
transformations are also reported as intramolecular and are influenced by the use of a 
tether.26   
 Admixture of a solution of furan 72 in THF and keto-ester 68 at 23 °C furnished, 
after concentration, a dark burgundy oil as a single regioisomeric product by NMR 
analysis.  Both proton and carbon spectra showed an enol ether and bridgehead methine 
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found in the expected product.  Bicycle 79 exhibited spectra consistent with an earlier 
variant of this system performed with a methyl carbonate instead of a pivaloyl ester 
which furnished the desired sense of regioselectivity, and was verified by 
crystallography. Bicycle 79 was then opened under acidic conditions, aromatizing to 
form phenol 81 with concomitant pivaloyl migration (Figure 23). 
 
 
 
Figure 23. Diels-Alder adduct and aromatization to phenol 81. 
With large quantities of phenol 81 in hand the current object was to determine how to 
convert it into an acetoacetylated chromanone 82 (Figure 24).   
 
 
 
Figure 24. Phenol to protected 5,6-DHP 82. 
It was discovered quickly that the free phenol required protection as transformations on 
81 were fraught with difficulty.  The phenol was then protected as its methoxymethyl 
ether and the resulting pentasubstituted arene 83 was desilylated under the action of 
potassium methoxide to furnish hydroxyacetophenone 84 in good yield over this two-step 
sequence (Figure 25). 
 
 
Figure 25. Synthesis of phenol 84. 
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Early attempts to engage the ortho-hydroxy functionality of 84 in Baker-Venkataraman 
chemistry failed to furnish acetoacetylated products (Figure 26).27,28   
 
 
 
Figure 26. Attempted Baker-Venkataraman chromone formation. 
The initial adduct 85 could be formed in situ or isolated, but the second step, the acyl 
transfer reaction never worked.  Rigorous exclusion of water showed no benefit and only 
mixtures of recovered 85 or hydroxyacetophenone 84 were recovered.  This can be 
attributed to the large steric bulk the ortho-tert-butyl ester imparts to the adjacent methyl 
ketone in 85.  Molecular models suggest enolization of the methyl ketone is impeded by 
steric compression and competitive hydrolysis of the phenolic ester becomes the 
dominant pathway.  Interestingly, enol silyl ethers could be formed.  Silylation was 
accomplished under the action of LDA and TMSCl, but the resulting bis-silyl compound 
did not productively engage any acyl electrophiles and this approach was not pursued 
further (Figure 27).   
 
 
Figure 27.  Attempted use of enolsilyl ether 87. 
Productive reactivity was observed in the piperidine-promoted aldol reaction of phenol 
84 and isovaleradehyde.29  The enone formed cyclizes to furnish 89 (Figure 28).  
 
 
Figure 28.  Aldol reaction and conjugate addition to furnish 89. 
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This was not expanded with a different aldehyde as the product would require 
functionalization and desaturation to arrive at the desired subtarget.   
In the course of course of these experiments the use of vinylogous amides became 
an attractive option for functionalizing phenol 84.  Enaminones 91 have been reported for 
the formation of halogenated and acylated chromones 92, primarily in the context of 
pharmaceuticals, but not extensively in natural product total synthesis (Figure 29).30,31   
 
 
 
Figure 29. Application of the Gammill reaction to chromone 92. 
While this reaction has been demonstrated on unprotected ortho-hydroxy acetophenones, 
it was thought that at elevated temperatures the methoxide generated from the ionization 
of DMF-DMA would desilylate phenol 83 in the process of furnishing the corresponding 
vinylogous amide.  In the event, phenol 83 was treated with excess DMF-DMA in hot 
toluene and gratifyingly vinylogous amide 93 was isolated in moderate yield (Figure 30).   
 
 
 
 
Figure 30. Formation of vinylogous amide 93. 
Toluene is the most utilized solvent for such transformations, however switching to 
dimethoxyethane greatly improved the yield of isolated product.  Presumably, a polar 
solvent stabilizes the ionization of DMF-DMA and lowers the energy of the reactive 
intermediates.   
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With vinylogous amide 93 in hand, the next objective was to affect 
acetoacetylation.  While acylation of enaminones are known through the use of activated 
acyl reagents, the following transformation has not been reported (Figure 31).32 
  
 
Figure 31.  Direct acetoacetylation of vinylogous amide 93. 
The first reagent used to examine the feasibility of this reaction was the most obvious and 
the one that was expected to work on the first attempt.  Diketene, however, did not 
furnish acetoacetylated product under several different reaction conditions.  It was found 
that the use of acyl-Meldrum’s acid 95 smoothly affected direct acetoacetylation of 
vinylogous amide 93 in good yield for this transformation (Figure 32).33  
 
 
 
Figure 32.  Direct acetoacetylation of vinylogous amide 94 with acyl Meldrum’s acid 96. 
The major byproducts from the reaction were chromanone 96 arising from competitive 
cyclization of the enamenone 93 and dehydroacetic acid 97 resulting from the Diels-
Alder cycloaddition of in-situ formed acyl-ketene from decomposition of 95 (Figure 33). 
 
 
 
 
Figure 33. Byproduct formation during acetoacetylation. 
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With protected 5,6-DHP 94 in hand, the deprotection was accomplished through 
the use of boron trichloride and furnished 5,6-DHP (53) in good yield (Figure 34).34   
 
 
Figure 34. Synthesis of 5,6-DHP (53). 
The key biomimetic dimerization sequence was now explored.  Heating 5,6-DHP (53) in 
deionized water lead to dimerization to form vinaxanthone (1) (Figure 35).    
 
 
 
Figure 35. Dimerization of 5,6-DHP (53) to form vinaxanthone (1). 
Further, no evidence of xanthofulvin was detected from the reaction.  Examining the 
mechanistic proposal suggests two explanations for the exclusive formation of the 
vinaxanthone connectivity.  Trienol 98 can undergo 6pi-electrocyclization to give 99 
which can engage in a reversible intramolecular conjugate addition furnishing 100.  This 
reversible conjugate addition suppresses the dehydration to form 101 (Figure 36).   
 
 
 
 
 
 
 
 
 
Figure 36. Mechanistic rationale for the exclusive formation of vinaxanthone (1). 
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The second feature which accounts for the formation of vinaxanthone over xanthofulvin 
is the aromaticity-assisted hydrogen bonding found in 103.35-37  Through resonance, the 
chromanyl unit in 102 can aromatize, stabilizing the transition state for the 6pi-
electrocyclization, in the cascade forming vinaxanthone (1) (Figure 37). 
 
 
 
 
Figure 37. Aromaticity assisted hydrogen bonding in 103. 
Having established a bioinspired synthesis of vinaxanthone (1), the next focus 
was to develop a laboratory preparation for larger quantities of vinaxanthone and one 
amenable to the synthesis of analogs and probes used in target identification studies.  
Acyl ketone 94 was found to be very reactive, and a system containing only a Michael 
acceptor would attenuate background reactivity.  It had been found that an alkynone 104 
could function as a surrogate for the acetoacetate functionality on 94 (Figure 38). 
 
 
 
Figure 38. Ynone 104 as a surrogate for acylketone 94. 
The route to ynone 104 was pursued as follows.  Iodination of enamenone 93 could be 
accomplished by treatment of the vinylogous amide with iodine in chloroform at 23 °C to 
furnish iodochromanone 105 as a white solid (Figure 39).30  
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Figure 39. Synthesis of iodochromanone 105. 
With significant quantities (20-30g) of this compound in hand the next 
transformation required was a Sonogashira coupling of iodochromanone 105 with 3-
butyn-2-ol 75.38-40  Initial conditions furnished low yields (35-40%) of coupled product 
106 with recovered iodochromanone 105 suggesting either no oxidative addition occurred 
in to the carbon-iodine bond or decomposition of the active catalyst was occurring.  It 
was found through degassing the THF that the yield could be augmented and was 
scalable to 3 to 5 grams (Figure 40).   
 
 
 
 
Figure 40. Sonogashira reaction of 105 to form carbinol 106. 
Oxidation of 106 proved to be non-trivial.  Oxidation methods including Swern, 
tetra n-propyl ammonium perruthenate (TPAP), or Dess-Martin reagent did not furnish 
product and destroyed the substrate.  Manganese dioxide oxidation was found to be batch 
dependent.  Corey-Schmidt oxidation worked consistently to smoothly oxidize carbinol 
106 to ynone 104 in reliable yield and on multi-gram scale (Figure 41).41   
 
 
 
Figure 41. PDC oxidation of 106 to furnish ynone 104. 
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It was thought that a cascade sequence between ynone 104 and protected 5,6-DHP 
93 would furnish vinaxanthone (1) (Figure 42).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Proposed cascade of ynone 104 and acyl ketone 93 to furnish protected vinaxanthone 114. 
Michael addition of 93 into ynone 104 would form adduct 107 which could 
eliminate to alkenes 108 and 109 which are interconvertible.  In each conjugate addition 
of the free phenol onto the alkene would furnish 110 and 111 which are both 
interconvertible.  Compounds 112 and 113 are expected to participate in 6pi-
electrocyclizations to form protected vinaxanthone 114 and protected 
 
104
93
107
108 109
110 111
112 113
101 114
tautomerize/6 -electrocyclization, -H2Otautomerize/6 -electrocyclization, -H2O
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dehydoxanthofuvlin 101,  although based upon the postulated reactivity for a 
xanthofulvin isomer to equilibrate back to 99, it was not expected to be detected in the 
reaction.  Exposure of a 1:1 ratio of protected 5,6-DHP 93 and ynone 104 to Et3N in 
acetonitrile at 23 °C did not furnish protected vinaxanthone 114 (Figure 43).  
 
 
 
Figure 43. Reaction of protected 5,6-DHP 93 and ynone 104. 
It was found, however, in control experiments that ynone 104 alone dimerized under the 
same reaction conditions affording protected vinaxanthone 114 (Figure 44).   
 
 
 
Figure 44. Homodimerization of ynone 104 to furnish protected vinaxanthone 114. 
This result is important, suggesting that an unknown variable is involved in the 
transformation of ynone 104 into protected vinaxanthone 114.  It was found in 
subsequent experiments that water is required for this transformation to work. Careful 
investigation in to the role of water is shown (Table 1).   
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Table 1. Optimization data for homodimerization to protected vinaxanthone 114. 
Based upon the optimization data, a proposed mechanism for the hydration of 
ynone 104 to keto-aldehyde 118  is shown below (Figure 45).   
 
 
 
 
 
 
 
Figure 45. Proposed hydration-isomerization mechanism of ynone 104 to keto-aldehyde 118. 
Addition of water into the chromone of 104 should furnish hemiacetal 115 which should 
eliminate to form aldehyde 116.  Addition of the proximal phenol into the alkynone 
should furnish, after isomerization, keto-aldehyde 118. Proof of concept for keto-
aldehyde 118 being a competent species in the proposed reaction sequence was obtained 
by converting ynone 104 to keto-aldehyde 118 through addition of 1000 equivalents of 
H2O to ynone 104 (Figure 46). 
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Figure 46. Isolation of keto-aldehyde 104 through hydration of ynone 118. 
Finally, treatment of isolated keto-aldehyde 104 and ynone 118 with Et3N in MeCN 
furnished protected vinaxanthone 114 in comparable yield to the in-situ conversion of the 
ynone 104 monomer to keto-aldehyde 118 (Figure 47). 
  
 
 
 
Figure 47. Heterodimerization of keto-aldehyde 118 and ynone 104 to furnish protected vinaxanthone 114. 
 Two possible mechanisms for this transformation can be invoked to explain the 
experimental results.  In the first mechanistic pathway keto-aldehyde 118 tautomerizes to 
the enolic form 119 and adds in a Michael fashion in to the ynone 104 forming an 
alleneol 120 which undergoes aldol addition in to the proximal aldehyde.  Dehydration 
forms protected vinaxanthone 114.  In the second pathway, keto-aldehyde 118 
tautomerizes to the dienol 121 which participates in a regioselective Diels-Alder 
cycloaddition with ynone 104.  Analogously, dehydration forms protected vinaxanthone 
114 (Figure 48).   
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Figure 48. Mechanistic rationale in the dimerization reaction of ynone 108 to furnish protected vinaxanthone 116. 
It is speculated that the Diels-Alder pathway is operative.  The low pKa of the ketonic 
protons should allow for facile dienol formation and the resultant enol should hydrogen 
bond to the ketone of the chromanone.  This pathway has also been used to furnish a 
cycloadduct of keto-aldehyde and DMAD.  This transformation only works with doubly-
activated alkynes (Figure 49). 
   
 
 
Figure 49. Adduct formation 122 with keto-aldehyde 118 and DMAD. 
Mono-activated alkynes fail to react productively, giving low yields of recovered keto-
aldehyde 118 with polymeric side products.  This reactivity is being used to synthesize 
analogs to be used in biological testing. 
 With several methods for the synthesis of protected vinaxanthone 114, the 
remaining goal was to simultaneously remove all phenolic and carboxylic acid protecting 
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groups.  This was accomplished with BCl3 in methylene chloride at room temperature, 
furnishing synthetic vinaxanthone (1) which matched all previously reported 
spectroscopic values (Figure 50).42-44 
 
 
 
 
Figure 50. Synthesis of vinaxanthone (1). 
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Experimental Section - General Information 
All reactions were performed in flame dried round bottom or modified Schlenk 
(Kjedahl shape) flasks fitted with rubber septa under a positive pressure of argon, unless 
otherwise indicated.  Air-and moisture-sensitive liquids and solutions were transferred by 
syringe or canula.  Where necessary (so noted), solutions were deoxygenated by 
alternative freeze (liguid-N2)/evacuation/thaw cycles (> three iterations).  Organic 
solutions were concentrated by rotary evaporation at ~ 20 torr.  Dichloromethane 
(CH2Cl2), tetrahydrofuran (THF) were purified using a Pure-Solv MD-5 Solvent 
Purification System (Innovative Technology).  Acetonitrile (MeCN) was purified using a 
Vac 103991 Solvent Purification System (Vacuum Atmospheres). Dimethoxyethane 
(DME) was purchased from Acros (99+%, stabilized with BHT), N,N-
dimethylformamide (DMF) was purchased from Acros (99.8%, anhydrous), methanol 
(MeOH) was purchased from Sigma-Aldrich (99.8%, anhydrous), ethanol (EtOH) was 
purchased from Pharmco-Aaper (200 proof, absolute). Chloromethyl methyl ether was 
prepared according to the method of Berliner.1  The method of Corey was used to prepare 
tert-butyldimethylsilyl triflate.2 All other reagents were used directly from the supplier 
without further purification unless noted.  Analytical thin-layer chromatography (TLC) 
was carried out using 0.2 mm commercial silica gel plates (silica gel 60, F254, EMD 
chemical) and visualized using a UV lamp and or ceric ammonium molybdate (CAM) or 
aqueous potassium permanganate (KMnO4) stain.  Infrared spectra were recorded on a 
Nicolet 380 FTIR using neat thin film technique.  High-resolution mass spectra (HRMS) 
were recorded on a Karatos MS9 and are reported as m/z (relative intensity).  Accurate 
40 
 
masses are reported for the molecular ion [M+Na]+, [M+H], [M+], or [M-H].  Nuclear 
magnetic resonance spectra (1H NMR and 13C NMR) were recorded with a Varian 
Gemini [(400 MHz, 1H at 400 MHz, 13C at 100 MHz), (500 MHz, 13C at 125 MHz), (600 
MHz, 13C at 150 MHz)].  For CDCl3 and CD3OD solutions the chemical shifts are 
reported as parts per million (ppm) referenced to residual protium or carbon of the 
solvents; CHCl3 δ H (7.26 ppm) and CDCl3 δ D (77.0 ppm) or CHD2OD δ H (3.34 ppm) 
or CD3OD δ C (49.0 ppm).  For CD2Cl2 and (CD3)2SO solutions the chemical shifts are 
reported as parts per million (ppm) referenced to residual protium or carbon of the 
solvents; CH2Cl2 δ H (5.32 ppm) and CD2Cl2 δ D (53.8 ppm) or (CH3)2SO δ H (2.50 
ppm) or (CD3)2SO δ C (39.5 ppm). For C6D6 and (CD3)2CO solutions the chemical shifts 
are reported as parts per million (ppm) referenced to residual protium or carbon of the 
solvents; C6H6 δ H (7.16 ppm) and C6D6 δ D (128.1 ppm) or (CH3)2CO δ H (2.05 ppm) 
and (CD3)2CO δ D (205.87 ppm for CO and 30.60 for CD3). Coupling constants are 
reported in Hertz (Hz).  Data for 1H-NMR spectra are reported as follows: chemical shift 
(ppm, referenced to protium; s = singlet, d = doublet, t = triplet, q= quartet, dd = doublet 
of doublets, td = triplet of doublets, ddd = doublet of doublet of doublets, m = multiplet, 
coupling constant (Hz), and integration). Melting points were measured on a MEL-TEMP 
device without corrections. 
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To a stirred solution of tetronic acid 73 (25.0 g, 250 mmol, 1.0 equiv.), 4-
dimethylaminopyridine, (1.53 g, 12.5 mmol, 0.05 equiv.) and N,N-diisopropylethylamine 
(45.8 mL, 262 mmol, 1.05 equiv.) in CH2Cl2 (500 mL) at 0 °C was added neat pivaloyl 
chloride (25.9 mL, 262 mmol, 1.05 equiv.) dropwise over 40 minutes. Upon complete 
addition the dark-brown solution was allowed to warm to 23 °C. After 16 hours the 
reaction mixture was concentrated in vacuo to give a dark-brown oil. The residue was 
suspended in Et2O (500 mL) and washed with H2O (500 mL). The aqueous layer was 
extracted with Et2O (5 x 500 mL) and the combined organic layers were dried over 
MgSO4 and concentrated in vacuo to give 74 (41.0 g, 223 mmol, 89%) as clear-amber 
crystals (m.p. 46-47 °C). 
Rf = 0.60 (silica gel, 1:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 6.00 (t, J = 1.4 
Hz, 1H), 4.91 (d, J = 1.4 Hz, 2H), 1.32 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 173.2, 
172.2, 169.1, 100.2, 68.2, 38.3, 26.4; IR (film, υ cm -1): 1779, 1746, 1072; m.p.: 46-47 
°C. 
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To a stirred solution of 74 (30.0 g, 163 mmol, 1.0 equiv.) in CH2Cl2 (226 mL) at 0 
°C was added triethylamine (29.8 mL, 212 mmol, 1.3 equiv.) in one portion. Neat tert-
butyldimethylsilyl triflate (37.8 mL, 165 mmol, 1.01 equiv.) was then added dropwise 
over 10 minutes. Upon complete addition the amber solution was allowed to warm to 23 
°C. After 1 hour the reaction mixture was concentrated in vacuo to give an amber oil. The 
residue was suspended in pentane (200 mL) and stirred for 1 hour. The organic layer was 
washed with sat. aq. NaHCO3 (100 mL), passed over solid NaHCO3 (10 g), filtered and 
washed with brine (100 mL). The organic layer was dried over potassium caronate and 
concentrated in vacuo to give furan 72 (37.9 g, 127 mmol, 78%). 
Rf = 0.55 (silica gel, 20:1 hexanes:EtOAc); 1H NMR (300 MHz, CDCl3): δ 7.10 (d, J = 
1.2 Hz, 1H), 5.15 (d, J = 1.2 Hz, 1H), 1.29 (s, 9H), 0.96 (s, 9H), 0.24 (s, 6H); 13C NMR 
(100 MHz, CDCl3): δ 175.3, 154.3, 139.4, 120.6, 80.1, 39.0, 27.1, 25.4, 18.0, -4.85; IR 
(film, υ cm -1): 3202, 3141, 1753, 1627; HRMS (ESI) calc. for C15H27O4Si [M+H]+: 
299.20000. Found: 299.20000.  
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Preparation #118,19 
 
 To a base-washed flask was added silver nitrate (5.39 g, 31.7 mmol, 2.0 equiv.) 
water (60 mL) and MeOH (30 mL).  Ammonium hydroxide was added dropwise (initially 
turning the solution into a dark brown heterogeneous solution) until the precipitate 
dissolved and the color dissipated. The flask was protected from light and purged with 
argon.  To this vigorously stirred solution was added tert-butyl propiolate (2.18 mL, 
15.85 mmol, 1.0 eq.) as a solution in MeOH (10 mL) over 2 hours.  The milky solution 
stirred for an additional 2 hours at 23 °C.  The solution was poured into a separatory 
funnel, and extracted with CCl4 once and chloroform three times. The combined organics 
were then washed with water three times, dried over CaCl2 and concentrated to reveal a 
brown/white solid. The solid was then diluted in CH2Cl2 (21 mL) and protected from 
light. Acetyl chloride (1.13mL, 15.85 mmol, 1 eq.) was added as a solution in CH2Cl2 (10 
mL). The solution stirred at 23 °C for 20 hours. The heterogeneous solution was diluted 
with diethyl ether, and the solids were filtered off. The ethereal layer was washed twice 
with pH 7 buffer (0.2M phosphate), brine and then dried over MgSO4. The solvent was 
removed yielding 27 as a brown, volatile liquid (1.25 g, 7.76 mmol, 49%). 
Rf = 0.40 (silica gel, 10:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 2.41 (s, 3H), 
1.52 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 182.8, 151.0, 85.4, 79.2, 79.0, 32.3, 27.9; 
IR (film, υ cm -1) 1716, 1689; HRMS (EC-CI) calc. for C9H13O3 [M+H]+: 169.0865. 
Found 169.0866. 
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Preparation #220 
 
To a stirred solution of 3-butyn-2-ol 75 (100 g, 1.43 mmol, 1.0 equiv.) and ethyl 
vinyl ether (151 mL, 1.57 mol, 1.1 equiv.) in CH2Cl2 (3 L) at 23 °C was added 
pyridinium p-toluenesulfonate (35.9 g, 143 mmol, 0.1 equiv.) in one portion. After 1 hour 
the clear solution was diluted with Et2O (1 L) and washed with brine (2 L). The organic 
layer was dried over Na2SO4 and concentrated in vacuo to give 76 as a mixture of 
diastereomers  (201 g, 1.41 mol, 99%) as a clear oil. 
Rf = 0.40 (silica gel, 1:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 4.96 (q, J = 5.5 
Hz, 1H), 4.85 (q, J = 5.5 Hz, 1H), 4.50 (q, J = 6.7 Hz, 1H), 4.35 (q, J = 6.7 Hz, 1H), 3.75 
(m, 1H), 3.62 (m, 1H), 3.53 (m, 2H), 2.40 (s, 1H), 2.39 (s, 1H), 1.46 (d, J = 3.1 Hz, 3H), 
1.44 (d, J = 3.1 Hz, 3H), 1.35 (d, J = 2.7 Hz, 3H), 1.34 (d, J = 2.7 Hz, 3H), 1.21 (t, J = 
7.0 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 98.5, 97.5, 84.5, 83.6, 72.4, 72.0, 61.1, 
60.5, 60.0, 59.9, 22.3, 21.9, 20.0, 19.9, 15.2, 14.9; HRMS (EC-CI) calc. for C8H13O2 
[M+H]+: 141.0916. Found: 141.0918. 
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To a stirred solution of 76 (110 g, 774 mmol, 1.0 equiv.) in THF (4.5 L) at −78 °C 
was added a solution of n-butyllithium in hexanes (2.0 M, 404 mL, 808 mmol, 1.05 
equiv.). After 15 minutes neat liquid di-tert-butyl dicarbonate (186 mL, 808 mmol, 1.05 
equiv.) was added over 10 minutes. Upon complete addition the amber solution was 
allowed to warm to 23 °C. The reaction mixture was diluted with Et2O (1.5 L) and 
washed with H2O (3 L) and brine (3 L). The organic layer was dried over MgSO4 and 
concentrated in vacuo to give 77 as a mixture of diasteromers as an amber oil (180 g, 743 
mmol, 96%). 
Rf = 0.21 (silica gel, 20:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 4.91 (q, J = 
5.1 Hz, 1H), 4.82 (q, J = 5.1 Hz, 1H), 4.56 (q, J = 6.8 Hz, 1H), 4.40 (q, J = 6.8 Hz, 1H), 
3.73 (m, 1H), 3.62 (m, 1H), 3.56 (m, 1H), 3.50 (m, 1H), 1.49 (s, 18 H), 1.46 (d, J = 1.7 
Hz, 6H), 1.34 (d, J = 1.4 Hz, 6H) 1.12 (t, J = 8.5 Hz, 6H); 13C NMR (100 MHz, C6D6): δ 
152.6, 152.5, 99.3, 98.3, 86.1, 85.2, 82.9, 82.7, 78.3, 77.9, 61.0, 60.4, 60.3, 60.2, 27.8 (2 
signals), 21.8, 21.5, 20.1, 20.0, 15.5, 15.3; IR (film, υ cm -1): 1710, 1274, 1160;  HRMS 
(ESI) calc. for C13H22NaO4 [M+Na]+: 265.14103. Found: 265.14100. 
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To a stirred solution of 77 (117g, 483 mmol, 1.0 equiv.) in EtOH (4.8 L) at 78 °C 
was added pyridinium p-toluenesulfonate (12.1g, 48.3 mmol, 0.1 equiv.) in one portion. 
After 2 hours the amber solution was allowed to cool to 23 °C. The reaction mixture was 
diluted with Et2O (2.4 L) and washed with brine (4 L). The organic layer was dried over 
MgSO4 and concentrated in vacuo to give 78 (73.1 g, 429 mmol, 89%) as an amber oil. 
Rf = 0.30 (silica gel, 3:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 4.62 (m, 1H), 
2.13 (s, 1H), 1.51 (m, 12H); 13C NMR (100 MHz, CDCl3): δ 152.8, 86.8, 82.9, 77.5, 
57.8, 27.8, 23.1; IR (film, υ cm -1): 3400, 1709; HRMS (EC-CI) calc. for C9H15O3 
[M+H]+: 171.1021. Found: 171.1019. 
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To a stirred solution of 78 (73.0 g, 429 mmol, 1.0 equiv.) in Me2CO (1.2 L) at 0 
°C was added ice-cold Jones reagent (1.53 M (67.0 g CrO3, 58.0 mL conc. H2SO4 and 
160 mL H2O), 280 mL, 429 mmol, 1.0 equiv.) slowly over 15 mintues. After 30 minutes 
the iPrOH (40 mL) was added to neutralize any excess Jones reagent. The reaction 
mixture was diluted with CH2Cl2 (1 L) and filtered through silica gel (100 g) with 1:1 
pentane:Et2O (2 L). The filtrate was washed with H2O (1 L), sat. aq. NaHCO3 (1 L) and 
brine (1 L). The organic layer was dried over Na2SO4 and concentrated in vacuo to give 
keto-ester 68 (57.5 g, 342 mmol, 80%) as a clear-amber oil. 
Rf = 0.40 (silica gel, 10:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 2.41 (s, 3H), 
1.52 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 182.8, 151.0, 85.4, 79.2, 79.0, 32.3, 27.9; 
IR (film, υ cm -1): 1716, 1689; HRMS (EC-CI) calc. for C9H13O3 [M+H]+: 169.0865. 
Found: 169.0866. 
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To a stirred solution of furan 72 (70.4 g 236 mmol, 1.0 equiv.) in THF (212 mL) 
at 0 °C was added keto ester 68 (39.7 g, 236 mmol, 1.0 equiv.) in one portion. Upon 
complete addition the amber solution was allowed to warm to 23 °C. After 1 hour the 
reaction mixture was concentrated in vacuo to give 79 as a clear yellow oil. 
Rf = 0.35 (silica gel, 10:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 6.38 (s, 1H), 
5.24 (s, 1H), 2.43 (s, 3H), 1.47 (s, 9H), 1.25 (s, 9H), 0.90 (s, 9H), 0.20 (s, 3H), 0.18 (s, 
3H); 13C NMR (100 MHz, CDCl3): δ 199.3, 174.3, 167.7, 163.7, 161.2, 146.3, 118.5, 
113.9, 82.3, 78.2, 39.2, 30.7, 27.9, 26.8, 25.4, 17.7, -3.5, -3.7; IR (film, υ cm -1): 1769, 
1712; HRMS (EC-CI) calc. for C24H38O7Si [M+Na]+: 489.22790. Found: 489.22801. 
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To a stirred solution of bicycle 79 (110 g, 236 mmol, 1.0 equiv.) in THF (471 mL) 
at 0 °C was added a solution of dry hydrochloric acid in dioxane (4.0 M, 47.1 mL, 47.1 
mmol, 0.2 equiv.) slowly over 5 minutes. Upon complete addition the amber solution was 
allowed to warm to 23 °C. After 2 hours the reaction mixture was concentrated in vacuo 
to give an amber oil.  The crude material was purified via silica gel column 
chromatography (20:1 hexanes:EtOAc) to give phenol 81 (82.9 g, 178 mmol) as a clear, 
slightly yellow oil. 
Rf = 0.38 (silica gel, 10:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 10.91 (s, 
1H), 6.71 (s, 1H), 2.48 (s, 3H), 1.54 (s, 9H), 1.38 (s, 9H), 0.94 (s, 9H), 0.18 (s, 9H); 13C 
NMR (100 MHz, CDCl3): δ 202.3, 176.3, 168.4, 148.7, 142.5, 139.7, 131.9, 119.9, 
111.0, 85.7, 39.2, 32.5, 27.8, 27.2, 25.5, 18.0, -4.4; IR (film, υ cm -1): 1763, 1716, 1673; 
HRMS (EC-CI) calc. for C24H38O7Si [M+Na]+: 489.22790. Found: 489.22813. 
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To a stirred solution of phenol 81 (82.9 g, 178 mmol, 1.0 equiv.) in CH2Cl2 (1.7 
L) at 0 °C was added N,N-diisopropylamine (63.4 mL, 355 mmol, 2.0 equiv.). A solution 
of methoxymethyl chloride in PhMe/MeOAc (2.1 M, 127 mL, 267 mmol, 1.5 equiv.) was 
then added slowly over 20 minutes.  Upon complete addition the amber solution was 
allowed to warm to 23 °C.  After 1 hour the reaction mixture was diluted with 0.1 M HCl 
(500 mL) and extracted with CH2Cl2 (500 mL). The organic layer was dried over Na2SO4 
and concentrated in vacuo to give an amber oil.  The crude material was purified via 
silica gel column chromatography (10:1 hexanes:EtOAc) to give acetophenone 83 (61.4 
g, 120 mmol, 68%) as a white solid (m.p. 60-62 °C). 
Rf = 0.61 (silica gel, 3:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 6.76 (s, 1H), 
5.10 (s, 2H), 3.42 (s, 3H), 2.54 (s, 3H), 1.49 (s, 9H), 1.34 (s, 9H), 0.97 (s, 9H), 0.21 (s, 
9H); 13C NMR (100 MHz, CDCl3): δ 200.9, 175.7, 163.5, 150.9, 150.4, 132.8, 128.1, 
125.7, 108.6, 94.6, 82.5, 55.9, 38.9, 31.7, 27.7, 27.1, 25.6, 18.1, -4.4; IR (film, υ cm -1): 
1761, 1733, 1703; HRMS (ESI) calc. for C26H42NaO8Si [M+Na]+: 533.25412. Found 
533.25387; m.p.: 60-62 °C. 
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To a stirred solution of acetophenone 83 (15.4 g, 30.2 mmol, 1.0 equiv.) in DME 
at 85 °C was added N,N-dimethylformamide dimethyl acetal (16.1 mL, 121 mmol, 4.0 
equiv.) in one portion. After 3 hours the amber solution was cooled to 23 °C and then 
concentrated in vacuo to give enaminone 93 as a dark amber oil of sufficient purity for 
subsequent steps. However, when the crude material was purified via silica gel column 
chromatography (1:1 hexanes:EtOAc) enaminone 93 (8.59 g, 19.0 mmol, 63%) was 
obtained as an orange solid (m.p. 118-119 °C). 
Rf = 0.26 (silica gel, 1:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 12.43 (bs, 
1H), 7.77 (d, J = 12.2 Hz, 1H), 6.70 (s, 1H), 5.49 (d, J = 12.2 Hz, 1H), 5.13 (s, 2H), 3.41 
(s, 3H), 3.15 (s, 3H), 2.84 (s, 3H), 1.47 (s, 9H), 1.34 (s, 9H); 13C NMR (100 MHz, 
CDCl3): δ 189.4, 175.8, 165.6, 159.3, 154.4, 151.6, 130.1, 128.5, 113.7, 104.0, 95.2, 94.0, 
82.4, 56.0, 45.1, 38.7, 37.1, 27.6, 27.0; IR (film, υ cm -1): 1751, 1716, 1632, 1111; 
HRMS (ESI) calc. for C23H33NNaO8 [M+Na]+: 474.20984. Found: 474.21058; m.p.: 
118-119 °C. 
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To a solution of 93 (1.44 g, 3.19 mmol, 1.0 eq.) in toluene (32 mL) was added 
freshly ground acyl Meldrum’s acid 95 (1.78 g, 9.57 mmol, 3.0 eq.).  The amber solution 
was heated to 110 °C for 45 minutes then cooled to 23 °C and concentrated in vacuo to 
give a brown solid.  The crude material was purified via acidified silica gel* column 
chromatography (7:1 hexanes: EtOAc), yielding 94 (650 mg, 1.33 mmol, 42%) as a 
yellow solid (m.p. = 181-182 °C).   
Rf = 0.24 (silica gel, 3:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) δ 15.87 (s, 1H), 
8.66 (s, 1H), 7.23 (s, 1H), 7.05 (s, 1H), 5.24 (s, 2H), 3.45 (s, 3H), 2.22 (s, 3H), 1.65 (s, 
9H), 1.38 (s, 9H); 13C NMR (100 MHz, CDCl3, The highly concentrated 13C sample 
produced a mixture of keto and enol tautomers) δ 202.5, 197.6, 192.1, 174.3, 172.6, 
163.6, 161.7, 159.4, 154.5, 154.2, 153.4, 136.7, 128.6, 120.9, 118.0, 116.3, 115.8, 103.9, 
103.8, 101.7, 94.7, 83.1, 57.7, 56.7, 56.6, 39.2, 30.7, 28.2, 27.2, 26.9; IR (film, cm -1) 
1762, 1734, 1663, 1621; HRMS (ESI) calcd. for C25H30NaO10 [M+Na]+ 513.17312 found 
513.17341. 
*To a 4 L Erlenmeyer flask was added 400 g of silica gel. Added was 2.50 L of deionized 
water and the slurry stirred vigorously. The solution was acidified to a pH of 2 with 6.50 
mL of 85% phosphoric acid. The slurry stirred for 20 minutes. The silica gel was filtered 
and washed with ethyl acetate, then dried in a 120 °C oven overnight. 
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To a solution of 94 (50.0 mg, 0.102 mmol, 1.0 equiv.) in CH2Cl2 (10 mL) 0 °C 
was added boron trichloride solution (1.0 M in CH2Cl2, 1.22 mmol, 1.22 mL, 12.0 
equiv.). The red heterogeneous solution was warmed to 23 °C and stirred for 1 hour. The 
reaction was then cooled to 0 °C and quenched with 2 mL of 2N HCl, and stirred at 0 °C 
for 5 minutes. The solution was diluted with ethyl acetate (30 mL) and the pH of the 
aqueous layer was adjusted to a pH of 7 using a pH 10 buffer (40 mL of 0.2 M phosphate 
buffer). The layers were separated and the organic layer was extracted three times with 
additional pH 7 buffer (30 mL of 0.2 M phosphate buffer). The combined aqueous 
washes were re-acidified to a pH of 2 using 2N HCl and extracted with ethyl acetate (3 x 
30 mL). The organic layers were washed with brine (50 mL), dried over MgSO4 and 
concentrated in vacuo to yield 5,6-dehydropolivione (53) (20.1 mg, 0.098 mmol, 96% 
yield) as a yellow solid (m.p. = 231-232 °C). Rf= 0.54 (silica gel, 90:10 EtOAc:AcOH); 
1H NMR (400 MHz, (CD3)2SO) δ [enol] 16.10 (bs, 1H), 12.71 (bs, 1H), 11.55 (bs, 1H), 
9.50 (bs, 1H), 8.84 (s, 1H), 6.98 (s, 1H), 6.96 (s, 1H), 2.19 (s, 3H), [keto] 12.71 (bs, 1H), 
11.55 (bs, 1H), 9.50 (bs, 1H), 8.73 (s, 1H), 6.96 (s, 1H), 4.09 (s, 2H), 2.20 (s, 3H);  13C 
NMR (100 MHz, (CD3)2SO) δ [enol] 196.7, 176.0, 172.3, 167.4, 160.2, 152.6, 149.8, 
142.0, 120.2, 116.2, 113.2, 102.4, 100.8, 26.3, [keto] 203.0, 192.7, 173.0, 161.7, 152.6, 
150.1, 120.4, 120.2, 113.6, 102.5, 57.4, 30.6; IR (film, cm -1) 3280, 1617, 1473; HRMS 
(ESI) calcd. for C14H9O8 [M-H]- 305.03029 found 305.03013. 
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5,6-dehydropolivione (53) (10.0 mg, 0.033 mmol, 1.00 eq) in water (0.327 mL) 
stirred at 55 °C for 4 days. The reaction was quenched with 2 mL of conc. ammonium 
hydroxide. The solution was washed with ethyl acetate (2 x 20 mL), and then re-acidified 
to a pH of 1 using conc. HCl at 0 °C. The crude material was extracted with ethyl acetate 
(3 x 20 mL), washed with pH 2 buffer (20 mL), then brine (30 mL) before drying over 
magnesium sulfate, yielding vinaxanthone (1), (5.7 mg, 0.0099 mmol, 61%) as a yellow 
solid after trituration with methanol (3 x 1mL portions). 
Rf= 0.05 (sílica gel, 95:5 EtOAc:AcOH); 1H NMR (400 MHz, (CD3)2SO) δ 12.89 (bs, 
1H), 12.72 (bs, 1H), 11.69 (bs, 1H), 11.44 (bs, 1H), 9.42 (bs 2H), 9.42 (bs, 2H), 8.53 (s, 
1H), 8.18 (s, 1H), 6.96 (s, 1H), 6.94 (s, 1H), 2.55 (s, 3H), 2.53 (s, 3H); 13C NMR (125 
MHz, (CD3)2SO) δ 201.1, 199.1, 172.9, 172.6, 167.4, 167.4, 154.1, 152.7, 152.5, 152.1, 
150.7, 150.3, 141.7, 141.0, 136.2, 133.4, 132.6, 126.3, 120.8, 120.5, 119.8, 119.6, 112.4, 
110.0, 102.4, 102.3, 32.1, 29.1; IR (KBr, cm -1) 3236, 1683, 1653, 1472, 1288; HRMS 
(ESI) calc. For C28H15O14 [M-H]-: 575.04673, obs. 575.04679; m.p. >280 °C. 
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To a stirred solution of enaminone 93 (13.6 g, 30.2 mmol, 1.0 equiv.) in CHCl3 
(302 mL) at 23 °C was added solid iodine (15.3 g, 60.4 mmol, 2.0 equiv.) in one portion. 
After 3 hours the black solution was diluted with aq. sat. Na2S2O3 (300 mL) and extracted 
with CH2Cl2 (300 mL). The organic layer was dried over Na2SO4 and concentrated in 
vacuo to give a tan solid. The crude material was purified via silica gel column 
chromatography (1:1 hexanes:EtOAc) to give iodochromone 105 (9.97 g, 18.7 mmol, 
62%; 9.65 g, 18.1 mmol, 60% over 2 steps) as a white solid (m.p. 189-190 °C). 
Rf = 0.32 (silica gel, 3:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 8.19 (s, 1H), 
7.17 (s, 1H), 5.23, (s, 2H), 3.25 (s, 3H), 1.64 (s, 9H), 1.37 (s, 9H); 13C NMR (100 MHz, 
CDCl3): δ 175.4, 170.9, 163.2, 156.8, 154.9, 153.3, 136.5, 128.3, 112.8, 103.5, 94.7, 86.7, 
83.3, 56.6, 39.2, 28.2, 27.2; IR (film, υ cm -1): 1764, 1731, 1650; HRMS (ESI) calc. for 
C21H25INaO8 [M+Na]+: 555.04863. Found: 555.04881; m.p.: 189-190 °C. 
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To a stirred solution of iodochromone 105 (3.0 g, 5.64 mmol, 1.0 equiv.), 
bis(triphenylphosphine) palladium (II) dichloride (396 mg, 0.56 mmol, 0.1 equiv.) and 
copper iodide (107 mg, 0.56 mmol, 0.1 equiv.) in degassed THF (56 mL) at 23 °C was 
added 3-butyn-2-ol 75 (1.8 mL, 22.5 mmol, 4.0 equiv.). Neat diisopropylamine (2.4 mL, 
16.9 mmol, 3.0 equiv.) was then added.  After 1 hour the reaction mixture was diluted 
with pH = 7.0 phosphate buffer (50 mL) and extracted with CH2Cl2 (50 mL). The organic 
layer was dried over Na2SO4 and concentrated in vacuo to give an amber oil.  The crude 
material was purified via silica gel column chromatography (1:1 hexanes:EtOAc) to give 
propargyl alcohol 106 (1.71 g, 3.60 mmol, 64%) as a tan solid (m.p. 132-134 °C). 
Rf = 0.21 (silica gel, 1:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 8.03 (s, 1H), 
7.14 (s, 1H), 5.21 (s, 2H), 4.75 (m, 1H), 3.43 (s, 3H), 3.20 (bs, 1H), 1.63 (s, 9H), 1.51 (d, 
J = 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 175.5, 173.3, 163.3, 157.5, 154.6, 
153.2, 136.3, 128.1, 114.5, 110.5, 103.8, 97.5, 94.6, 83.2, 73.8, 58.6, 56.6, 39.2, 28.2, 
27.2, 23.8; IR (film, υ cm-1): 3435, 1763, 1735, 1731, 1461; HRMS (ESI) calc. for 
C25H30NaO9 [M+Na]+: 497.1782. Found: 497.1785; m.p.: 132-134 °C. 
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To a stirred solution of propargyl alcohol 106 (5.0 g, 10.5 mmol, 1.0 equiv.) and 
activated 4.0 Å molecular sieves (2 g) in CH2Cl2 (105 mL) at 23 °C was added solid 
pyridinium dichromate (19.0 g, 52.7 mmol, 5.0 equiv.) in one portion. After 2 hours the 
black solution was filtered through a pad of Celite™ and concentrated in vacuo to give an 
amber oil. The crude material was purified via silica gel column chromatography (1:1 
hexanes:EtOAc) to give ynone 104 (2.79 g, 5.90 mmol, 56%) as a white solid (m.p. 178-
179 °C). 
Rf = 0.41 (silica gel, 1:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3): δ 8.20 (s, 1H), 
7.21 (s, 1H), 5.24 (s, 2H), 3.44 (s, 3H), 2.46 (s, 3H), 1.64 (s, 9H), 1.37 (s, 9H); 13C NMR 
(100 MHz, CDCl3): δ 184.2, 175.4, 172.1, 163.1, 160.4, 154.6, 153.7, 136.8, 128.3, 
114.6, 108.7, 104.0, 94.7, 93.5, 83.5, 81.0, 56.7, 39.2, 32.7, 28.2, 27.2; IR (film, υ cm-1): 
1762, 1734, 1672, 1620, 1459, 1264, 1246, 1155, 1091; HRMS (ESI) calc. for 
C25H28NaO9 [M+Na]+: 495.1626. Found: 495.1632; m.p.: 182-183 °C. 
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To a stirred solution of  104 (50 mg, 0.106 mmol, 1.0 equiv.) in MeCN (10.6 mL) 
at 23 °C was added H2O (1.91 mL, 106 mmol, 1000 equiv.). Neat triethylamine (150 uL, 
1.51 mmol, 10 equiv.) was then added.  After 1 hour the amber solution was dried over 
MgSO4 and concentrated in vacuo to give keto-aldehyde 118 (29 mg, 0.059 mmol, 56%) 
as an amber solid (m.p. 178-179 °C (decomp)) of sufficient purity for subsequent steps. 
Rf = 0.23 (silica gel, 1:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) δ 10.42 (s, 1H), 
7.20 (s, 1H), 5.23 (s, 2H), 4.26 (bs, 2H), 3.45 (s, 3H), 2.38 (s, 3H), 1.64 (s, 9H), 1.39 (s, 
9H); 13C NMR (125 MHz, CDCl3) δ 200.0, 190.7, 175.4, 175.0, 168.5, 163.3, 154.5, 
153.9, 136.7, 128.2, 117.4, 115.5, 104.1, 94.8, 83.4, 56.6, 47.5, 39.2, 30.7, 28.2, 27.2; IR 
(film, υ cm-1) 3420, 1762, 1730, 1653, 1595, 1458, 1265, 1157, 1029; HRMS (ESI) calc. 
for C25H30NaO10 [M+Na]+: 513.17312, obs. 513.17312. 
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To a stirred solution of 118 (25 mg, 0.051 mmol, 1.0 equiv.) and dimethyl 
acetylenedicarboxylate (15) (31 uL, 0.255 mmol, 5.0 equiv.) in MeCN (0.5 mL) at 23 °C 
was added triethylamine (36 uL, 0.205 mmol, 5.0 equiv.).  After 1 hour the black solution 
was concentrated in vacuo to give a black oil. The crude material was purified via silica 
gel column chromatography (2:1 hexanes:EtOAc) to give xanthone 122 (14 mg, 0.022 
mmol, 45%) as a white solid (m.p. 194-195 °C). 
Rf = 0.22 (silica gel, 2:1 hexanes:EtOAc); 1H NMR (400 MHz, C6D6) δ 8.91 (s, 1H), 
6.75 (s, 1H), 4.67 (s, 2H), 3.69 (s, 3H), 3.39 (s, 3H), 3.09 (s, 3H), 2.45 (s, 3H), 1.78 (s, 
9H), 1.40 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 199.1, 175.5, 172.8, 166.8, 164.7, 
163.2, 154.9, 154.4, 153.8, 137.9, 136.1, 131.0, 130.9, 129.0, 125.1, 121.8, 112.6, 103.5, 
94.8, 83.5, 56.8, 53.3, 52.9, 39.2, 32.2, 28.1, 27.2; IR (film, υ cm-1) 1733, 1463, 1271, 
1243, 1157, 1093; HRMS (ESI) calc. for C31H34NaO13 [M+Na]+: 637.18916, obs. 
637.18894. 
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Chapter 3   
Total Synthesis of Xanthofulvin and Structural Reassignment of 411J 
 In the paper suggesting the dimerization of two C14 polyketides in the biosynthetic 
pathway for the formation of vinaxanthone (1), a new natural product called 411J (123) 
was disclosed.1  Interestingly, the spectral data for 411J (123) in both keto and enol forms 
matched that of xanthofulvin (2).  In addition to our goal of synthesizing xanthofulvin 
(2), ambiguity in the structural assignment of 411J (123) could be cleared through the 
synthesis of xanthofulvin (2), the most plausible of the two structures (Figure 1).    
 
 
 
 
 
 
 
 
 
 
Figure 20. Equilibrating structures of xanthofulvin (2) and 411J (123) and their keto forms. 
Applying the proposal for the formation of vinaxanthone (1) and dehydroxanthofulvin 63, 
a postulated biosynthetic pathway can be seen for the direct synthesis of xanthofulvin (2) 
and one that accounts for the hemiketal in the proposed structure of 411J (123).  In this 
pathway, Michael addition of polivione (33) into 5,6-dehydropolivione (53) forms adduct 
(126) undergoing elimination to form isomeric alkenes 126 and 127 (Figure 2).2-5   
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Figure 21. Initial adduct formation between 5,6-DHP (53) and polivione (33). 
These isomers can interconvert readily at biological pH through anion 129 (Figure 3).   
 
 
 
 
 
Figure 22. Highly delocalized tetraketo anion 129. 
Alkenes 127 and 128 can then undergo condensation to chromones 130 and 131, which 
can interconvert due to extended conjugation.  Structures 130 and 131, are poised to react 
and cyclize (Figure 4).   
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Chromone condensation of 127 and 128. 
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It is likely they react in a 6pi- electrocyclization and in the event 130 and 131 tautomerize 
to their trienol forms undergoing electrocyclization to form 134 and 135 (Figure 5).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Tautomerization and 6pi-electrocyclization reactions to form 134 and 135. 
The resultant aldol-like adducts 134 and 135 undergo dehydrative elimination to furnish 
the aromatized adducts providing vinaxanthone (2) or 411J (123) (Figure 6).  
 
 
 
 
 
 
 
 
 
Figure 25. Formation of xanthofulvin (2) and 411J (123). 
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Initial experiments with this proposed biosynthetic pathway in the laboratory failed to  
furnish xanthofulvin (2) or 411J (123).  It is known that polivione (33) is unstable and 
was never re-isolated from any of the reaction mixtures.6  Based upon these results, the 
biomimetic cascade approach to xanthofulvin (2) was modified. A central focus was to 
incorporate a biomimetic 6pi-electrocyclization in the synthesis of the tricyclic flank.7  
Retrosynthetically, xanthofulvin (2) was simplified to enedione 101 through sequential 
protecting group and reduction transforms (Figure 7). 
 
 
 
Figure 26.  Retrosynthesis of xanthofulvin (2). 
Enedione 101 can be simplified to enaminone 93 and carboxylic acid 136 through 
reduction and O→C carboxyl transfer transforms.  Carboxylic acid 136 can be formed the 
methyl ester 137 (Figure 8).   
 
 
 
 
 
 
Figure 27.  Retrosynthesis to subtargets 93 and 137. 
At this point the major objective was to develop a synthesis of methyl ester 137 and 
initial efforts were focused on advancing ketal 138 through a 6pi-electrocyclization to 
arrive at 140 (Figure 9).8   
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Figure 9. Electrocyclization route to tricyclic methyl ester 140. 
While this approach was satisfactory, it suffered from significant drawbacks.  
Deprotection of the ketal was accompanied by loss of the methoxymethyl protecting 
group complicating purification and would require reinstallation of a protecting group, 
something considered to be avoidable at this stage in the synthesis.  Saponification of the 
methyl ester was extremely sluggish and hydrolysis of the pivaloyl ester was competitive.  
Additionally, this transformation was not scalable.  Fortuitously, an interesting 
transformation involving 3-alkynyl chromanones was found to be a possible solution to 
this tricyclic methyl ester problem.  This reaction, published by Hu and coworkers, is the 
addition of a stabilized nucleophile (β-ketoesters or β-diketones) into the 2-position of a 
3-alkynyl chromanone.9-11  This is an extension of known reactivity of 3-formyl or 3-
ketonic chromanones.12,13  The parent transformation, and the substrate which suggested 
this to be a feasible option is shown (Figure 10).   
 
 
 
 
Figure 10. Formation of substituted tetracycle 142 from 3-alkynyl chromanone by Hu and co-workers.9-11 
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Interestingly, the only substrates reported in this paper contained terminal aryl or alkyl 
groups but the use of ynone 104 as a Michael acceptor was extended to this 
transformation.  The reaction was run with methyl acetoacetate and the expected product 
137 was obtained in a low, but significantly important yield (Figure 11).   
 
 
 
Figure 11. Initial rearrangement with ynone 95. 
The focus now was to optimize this transformation into something synthetically useful.  
A brief screen of bases found sodium hydride to be competent and better results were 
found by forming the sodium enolate 138 of methyl acetoacetate prior to addition into a 
solution of ynone 104. THF was found to be the optimal solvent.  Optimization is 
summarized and the yields are of isolated, purified material (Figure 12). 
 
 
 
 
 
 
 
Figure 12. Optimization of rearrangement reaction in the synthesis of tricyclic methyl ester 137. 
This transformation was found to be moderately scalable (500 mg) and furnished good 
quantities of methyl ester 137.  A proposed mechanism for the transformation is shown 
(Figure 13).   
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Figure 13. Proposed mechanism for the formation of tricyclic methyl ester 137. 
 Saponification was accomplished with a slight excess (1.2 equiv.) of aqueous 
sodium hydroxide in THF furnishing carboxylic acid 136 as a white solid which did not 
require purification for subsequent steps (Figure 14).   
 
 
 
 
Figure 14. Hydrolysis of 137 to furnish carboxylic acid 136. 
This transformation, while straightforward, required extended reaction times of 30-40 
hours.  Increasting the equivalents of sodium hydroxide induced hydrolysis of both of the 
methyl and pivaloyl esters.  The carboxylic acid 136 was reacted with oxalyl chloride in 
the presence of pyridine in benzene to afford the acid chloride 149, which was taken on 
in crude form to the O→C carboxyl transfer step.  These reaction conditions were chosen 
for mildness and the pyridinium chloride formed is insoluble in benzene and can be 
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filtered away.  The carboxyl transfer was accomplished in moderate yield and several 
amine bases and solvents were used to determine the optimal conditions.  All conditions 
employing acid chloride 149 were essentially equivalent with regard to yield. A 
representative result is shown (Figure 15).   
 
 
 
 
 
Figure 15.  Carboxyl transfer reaction using acid chloride 149. 
The use of acid chlorides or other activated carboxylic acid surrogates, such as 
acyl imidazolides, have typically been employed for such transformations.14-16 It was 
thought that the use of the free carboxylic acid with a coupling reagent might furnish the 
product in greater yield.  Additionally, this would eliminate the step of preparing the acid 
chloride.  The use of DCC or EDCI showed an improvement in yield compared to the 
acid chloride strategy, furnishing aminal 150 in 60% yield.  However, chromatographic 
purification became tedious to remove the urea byproducts and work up conditions were 
not amenable to urea separation due to the basicity of the aminal.  The use of PyBOP or 
similar reagents showed no improvement beyond the yields found with the acid chloride 
strategy.  Employing HBTU showed a significant improvement in the yield of this 
transformation, furnishing aminal 150 in high yield through the presumed intermediate 
phenolic ester 151.17  To the best of our knowledge this is the first example of  an 
enaminone O→C carboxyl transfer reaction proceeding directly with a carboxylic acid, 
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and this is one of the most hindered substrates applied to this type of transformation 
(Figure 16). 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Carboxyl transfer using carboxylic acid 136 to form aminal 150. 
Additionally, this reaction does not require chromatographic purification.  Workup with 
an admixture of hexanes and ethyl acetate and saturated LiCl washings furnish material 
of high purity which can be taken on to subsequent steps with no decrease in yield.  This 
has allowed for the late stage advancement of 2-3 gram batches of aminal 150.  
Transforming aminal 150 into enedione 101 now became the next task. 
Spectroscopically, aminal 150 displays a 13.3 Hz coupling constant for the chromanyl 
methine proton flanked by the two carbonyl groups (Figure 17).   
 
 
 
 
 
 
Figure 17. Aminal 150 stereochemistry. 
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This is highly suggestive of a trans diaxial relationship and it was thought that 
thermolysis of 150 would induce a syn-elimination of dimethylamine to furnish enedione 
101.  Heating a solution of aminal 150 in toluene at reflux did not induce elimination and 
only starting material was recovered even after extended reaction times (Figure 18).   
 
 
 
 
Figure 18. Attempt at thermal elimination to form enedione 101. 
Attention was now focused on an acid promoted elimination to furnish enedione 101.  A 
brief screen of Br∅nsted acids showed pyridinium chloride to be  the most effective, and 
that acetonitrile was the optimal solvent.  Other Br∅nsted acids were either ineffective, 
returning unreacted starting material, or were too vigorous promoting cleavage of the 
protecting groups (Figure 19). 
 
 
 
 
 
Figure 19. Formation of enedione 135. 
 Examining conditions for the reduction of chromanyl enediones found that 
borohydrides are generally useful.18,19 Reduction of enedione 101 was accomplished 
under the action of NaCNBH3 in MeOH to smoothly, and rapidly (20 min.), furnishing 
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protected xanthofulvin 152.  This reaction has also been scaled to over 300 mg (Figure 
20).   
 
 
 
Figure 20. Reduction of 101 to form protected xanthofulvin 152. 
It should be noted that attempts were made to convert aminal 150 directly to protected 
xanthofulvin 152 through reduction of the dimethylamino moiety.  The use of silane 
reductants failed to furnish the desired product 152 and returned unreacted starting 
material, and the use of borohydride reductants furnished the reductive amination product 
153 in high yield (Figure 21).   
 
 
 
 
 
 
Figure 21.  Attempted reduction of aminal 152 to form protected xanthofulvin 155. 
There is ample literature precedent for reduction where the aminal nitrogen is endocyclic 
and the oxygen substituent is exocyclic.20  However, to the best of our knowledge there is 
no literature precedent for the opposite case where the aminal nitrogen is exocyclic 
(Figure 22).   
 
 
 
Figure 22. Endocyclic and exocyclic aminals. 
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In the absence of acid, reduction occurred with borohydride reagents.  It is likely that the 
aminal ionized to the zwitterionic, releasing the phenoxide and the dimethylamino 
iminium was reduced rapidly in the presence of hydride. 
The final step, deprotection of all oxygen bound protecting groups was 
accomplished with BCl3 in methylene chloride in high yield to furnish synthetic 
xanthofulvin (2) as a bright yellow solid.  It is of note that this is an interesting example 
of an aryl pivaloate deprotection accomplished under non-basic conditions.21 (Figure 23).   
 
 
 
 
Figure 23. Formation of xanthofulvin (2). 
Synthetic xanthofulvin matched all reported spectral values for isolated xanthofulvin (2) 
and 411J (123).22  The first total synthesis of xanthofulvin (2) and the accompanied 
structural reassignment of 411J (123) to that of xanthofulvin (2) has been accomplished.23   
Current efforts are focused on the synthesis of analogs.  The strategy of using an 
advanced tricycle and vinylogous amide allows for the synthesis of 64 possible 
xanthofulvin analogs based on the arene substitution patterns (Figure 24).   
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Figure 24. Monomers to be used in the synthesis of chemically edited xanthofulvin (2) analogs. 
Selective deletion of a phenolic residue or carboxylic acid will furnish a library of 
chemically edited derivatives.  These analogs will help elucidate the exact mechanism of 
action of xanthofulvin (2) through structure-activity relationship studies and target 
identification. 
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Experimental Section 
 
To a stirred suspension of sodium hydride (60% dispersion in mineral oil, 556 
mg, 13.9 mmol, 1.0 equiv.) in THF (55.7 mL) was added methyl acetoacetate (1.50 mL, 
13.9 mmol, 1.0 equiv.) dropwise over 5 minutes to furnish a 0.25 M stock solution of the 
sodium enolate of methyl acetoacetate (stored in a schlenk flask under argon).  To a 
stirred solution of ynone 104 (500 mg, 1.06 mmol, 1.0 equiv.) in THF (88 mL) at −78 °C 
was added a solution of the sodium enolate of methyl acetoacetate (0.25 M THF, 8.50 
mL, 2.12 mmol, 2.0 equiv.) 138 dropwise down the side of the flask over 10 minutes.  
Upon complete addition the red-amber solution was allowed to stir at −78 °C and after 5 
h, the excess sodium enolate of methyl acetoacetate was quenched with aqueous HCl (1.0 
M, 1.5 mL).  The resulting yellow solution was diluted with EtOAc (150 mL), washed 
with water (3 x 50 mL), brine (50 mL), dried over sodium sulfate, and concentrated in 
vacuo.  The yellow residue was chromatographed on silica gel (3:1 hexanes/EtOAc) to 
furnish methyl ester 137 (502 mg, 83 %) as a tan solid (m.p. 199-201 °C). 
 
Rf  = 0.40 (silica gel, hexanes/EtOAc  = 2:1); 1H NMR (400 MHz, CDCl3): δ 8.84 (s, 
1H), 7.17 (s, 1H), 5.27 (s, 2H), 3.93 (s, 3H), 3.47 (s, 3H), 2.67 (s, 3H), 2.62 (s, 3H), 1.67 
(s, 9H), 1.39 (s, 9H); 13C NMR (100 MHz, CD2Cl2): δ 202.4, 175.9, 173.6, 166.6, 163.8, 
154.8, 154.7, 153.4, 142.8, 135.8, 133.2, 129.9, 129.0, 127.6, 119.3, 112.7, 103.9, 95.1, 
83.5, 56.9, 52.6, 39.5, 32.9, 28.3, 27.4, 18.2; IR (film, υ cm-1): 1760, 1735, 1663, 1599; 
HRMS (ESI) calcd. for C30H34O11Na+ [M+Na]+: 593.19933. Found: 593.19976. 
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To a stirred solution of methyl ester 127 (920 mg, 1.61 mmol, 1.0 equiv.) in THF 
(65 mL) at 0 °C was added aqueous sodium hydroxide (0.1 M, 19.4 mL, 1.94 mmol, 1.20 
equiv.) dropwise over 2 minutes.  Upon complete addition the gold-orange solution was 
allowed to warm to 23 °C.  After 36 h the reaction was diluted with water (100 mL).  The 
solution was washed with ether (3 x 50 mL) and the aqueous layer was acidified by 
addition of 0.1 M HCl aq. (20 mL).  The clear aqueous layer was extracted with EtOAc 
(3 x 250 mL), dried over sodium sulfate and concentrated in vacuo to furnish carboxylic 
acid 136 (780 mg, 87%) as a white solid (mp: 203-204 °C) that was used in the next step 
without purification. 
 
1H NMR (400 MHz, CDCl3): δ 8.98 (s, 1H), 7.17 (s, 1H), 5.27 (s, 2H), 3.47 (s, 3H), 2.69 
(s, 3H), 2.65 (s, 3H), 1.67 (s, 9H), 1.39 (s, 9H); 13C NMR (150 MHz, CDCl3): δ 202.3, 
175.6, 173.2, 168.9, 163.5, 154.5, 154.4, 153.6, 143.1, 135.8, 133.0, 131.4, 129.0, 125.7, 
119.2, 112.8, 103.7, 94.8, 83.4, 56.7, 39.2, 32.8, 28.2, 27.3, 18.3; IR (film, υ cm-1):  
1760, 1688, 1666, 1619, 1596; HRMS (ESI) calcd. for C29H32O11Na+ [M+Na]+: 
579.18368. Found: 579.18373. 
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To a stirred solution of carboxylic acid 136 (373 mg, 0.67 mmol, 1.10 equiv.) in 
DMF (3.0 mL) at 23 °C was added solid O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (254 mg, 0.67 mmol, 1.1 equiv.) in one portion 
followed by N,N-diisopropylethylamine (0.27 mL, 1.52 mmol, 2.5 equiv.).  The dark 
amber solution was stirred for 5 min. and then solid enaminone 93 (275 mg, 0.61 mmol, 
1.10 equiv.) was added in one portion.  The reaction was stirred for 6 h then diluted with 
1:1 hexanes/EtOAc (100 mL) and washed with saturated aqueous LiCl solution (8 x 30 
mL).  The organic layer was dried over sodium sulfate and concentrated in vacuo.  The 
tan residue was chromatographed on silica gel (1:2 hexanes/EtOAc with 2% Et3N) to 
furnish aminal 150 (528 mg, 88 %) as a dark yellow solid (m.p. 124-126 °C).  
Rf  = 0.25 (silica gel, hexanes/EtOAc  = 1:1, 2% Et3N); 1H NMR (400 MHz, (CD3)2CO ): 
δ 8.87 (s, 1H), 7.42 (s, 1H), 7.30 (s, 1H), 5.46 (s, 2H), 5.28 (s, 2H), 5.23 (d, J = 13.3 Hz, 
1H), 3.47 (s, 3H), 3.44 (s, 3H), 3.07 (s, 3H), 2.86 (d, J = 13.3 Hz , 1H), 2.74 (s, 3H), 2.72 
(s, 3H), 2.59 (s, 3H), 1.64 (s, 9H), 1.44 (s, 9H), 1.37 (s, 9H), 1.35 (s, 9H); 13C NMR (125 
MHz, CDCl3 ): δ 202.2, 175.5, 175.3, 173.0, 163.9, 163.5, 157.5, 154.8, 154.5, 154.4, 
153.4, 149.4, 144.9, 143.2, 136.4, 136.3, 135.7, 132.9, 130.9, 128.9, 128.8, 126.1, 120.1, 
119.1, 112.7, 111.6, 103.6, 94.8, 94.7, 83.2, 83.1, 82.5, 56.7, 56.3, 44.9, 39.2, 39.0, 36.9, 
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32.8, 28.1, 27.7, 27.2, 27.1, 18.1;  IR (film, υ cm-1): 1766, 1730, 1660, 1610; HRMS 
(ESI) calcd. for C52H63NO18Na+ [M+Na]+: 1012.39374. Found: 1012.39398. 
 
 
To a stirred solution of aminal 150 (83.6 mg, 0.084 mmol, 1.0 equiv.) in 
acetonitrile (5.6 mL) was added solid pyridinium chloride (49 mg, 0.42 mmol, 5.0 equiv.) 
in one portion and the resulting yellow solution was heated to 65 °C.  After 18 h the 
reaction was concentrated and the yellow residue was chromatographed on silica gel (3:1 
hexanes/EtOAc 2:1 hexanes/EtOAc to furnish enedione 101 (54 mg, 68%) as a clear-
yellow solid (m.p. 185-188 °C). 
 
Rf  = 0.21 (silica gel, hexanes/EtOAc  = 1:1); 1H NMR (400 MHz, CDCl3): δ 8.43 (s, 
1H), 8.25 (s, 1H), 7.27 (s, 1H), 7.17 (s, 1H), 5.26 (s, 4H), 3.48 (s, 3H), 3.47 (s, 3H), 2.68 
(s, 3H), 2.45 (s, 3H), 1.61 (s, 9H), 1.42 (s, 9H), 1.38 (s, 9H), 1.35 (s, 9H); 13C NMR (125 
MHz, CDCl3): δ 202.2, 192.1, 175.5, 175.3, 173.2, 172.1, 163.5, 162.9, 160.4, 154.6, 
154.4, 154.3, 153.7, 152.6, 140.6, 136.8, 136.4, 135.6, 132.3, 128.9, 128.6, 127.3, 123.8, 
118.7, 116.5, 112.7, 104.0, 103.6, 94.8, 94.7, 83.2, 83.1, 56.7, 56.6, 39.2, 39.1, 32.7, 28.2, 
27.9, 27.3, 27.2, 17.5; IR (film, υ cm-1): 1760, 1732, 1663, 1607, 1591; HRMS (ESI) 
calcd. for C50H56O18Na+ [M+Na]+: 967.33589. Found: 967.33504. 
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To a stirred solution of endione 101 (30 mg, 0.032 mmol, 1.0 equiv.) in methanol 
(0.64 mL) at 23 °C was added solid sodium cyanoborohydride (4.0 mg, 0.063 mmol, 2.0 
eq) in one portion.  After 20 minutes the chalky yellow reaction mixture was diluted with 
aqueous pH 7.0 phosphate buffer (0.2 M, 0.25 mL) then diluted with EtOAc (10 mL).  
The organic phase was separated and the aqueous layer was extracted with EtOAc (2 x 10 
mL).  The combined organic layers were washed with brine (10 mL), dried over sodium 
sulfate, and concentrated in vacuo.  The yellow reside was chromatographed on silica gel 
(2:1 hexanes/EtOAc) to afford protected xanthofulvin 152 (27 mg, 91 %) as a bright 
yellow solid (mp: 184-186 °C). 
 
Rf  = 0.5 (silica gel, hexanes/EtOAc  = 1:1); 1H NMR (400 MHz, CDCl3): δ 15.43 (s, 
1H), 8.12 (s, 1H), 7.18 (s, 1H), 6.68 (s, 1H), 5.28 (s, 2H), 5.16 (s, 2H), 4.74 (bs, 2H), 3.48 
(s, 3H), 3.42 (s, 3H), 2.71 (s, 3H), 2.41 (s, 3H), 1.66 (s, 9H), 1.62 (s, 9H), 1.39 (s, 9H), 
1.37 (s, 9H); 13C NMR (150 MHz, CDCl3): δ 201.9, 183.6, 175.7, 173.3, 173.1, 163.9, 
163.6, 160.0, 154.9, 154.5, 152.3, 139.6, 135.7, 133.4, 132.4, 130.3, 129.3, 128.9, 126.9, 
119.2, 112.7, 111.9, 103.9, 103.8, 103.5, 94.8, 94.4, 93.4. 83.3, 82.9, 66.7, 56.7, 56.5, 
39.2, 39.1, 32.7, 29.7, 28.2, 28.1, 27.3, 27.2, 16.9; IR (film, υ cm-1): 1765, 1730, 1666, 
1602, 1458; HRMS (ESI) calcd. for C50H58O18Na+ [M+Na]+: 969.35154. Found: 
969.35120. 
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To a stirred solution of protected xanthofulvin 152 (20 mg, 0.02 mmol, 1.0 equiv.) 
in dry methylene chloride (2.1 mL) at 23 °C was added a solution of boron trichloride 
(1.0 M CH2Cl2, 0.25 mL, 0.25 mmol, 12 eq) and the reaction was stirred for 45 minutes 
then the yellow-orange solution was treated with aqueous HCl (12 M, 0.09 mL) and 
diluted with ethyl acetate (10 mL).  The bright orange solution was stirred vigorously for 
15 minutes and then concentrated in vacuo. The orange residue was diluted with 
methanol (15 mL) and re-concentrated in vacuo.  The yellow residue was triturated with 
cholorform (10 mL) and then filtered.  The yellow solid was then dried in vacuo to 
furnish xanthofulvin (2) (11.8 mg, 98%) as a 3.6:1 ratio of enol:keto tautomers as a bright 
yellow solid (m.p. 252-253 °C).  
 
Rf  = 0.14 (silica gel, EtOAc/AcOH  = 20:1); 1H NMR (500 MHz, (CD3)2SO): Enol: 
δ 15.61 (s, 1H), 12.75 (s, 1H), 11.62 (s, 1H), 11.23 (s, 1H), 9.33 (s, 1H), 8.69 (s, 1H), 
7.95 (s, 1H), 6.93 (s, 1H), 6.39 (s, 1H), 4.66 (s, 2H), 2.70 (s, 3H), 2.31 (s, 3H).  Keto: 
δ 11.15 (s, 1H), 8.88 (s, 1H), 8.51 (s, 1H), 6.92 (s, 1H), 6.42 (s, 1H), 5.01 (dd, J = 4.7 Hz, 
8.1 Hz, 1H), 4.71 (dd, J = 4.2 Hz, 11.3 Hz, 1H), 4.60 (m, 1H), 2.67 (s, 3H), 2.29 (s, 3H).   
13C NMR (125 MHz, (CD3)2SO): Enol: 202.6, 183.7, 172.7, 172.7, 167.5, 167.5, 156.3, 
154.5, 153.9, 152.2, 150.2, 140.8, 137.6, 132.4, 129.4, 128.3, 125.9, 120.7, 120.7, 118.7, 
110.1, 104.4, 102.4, 102.4, 65.9, 32.4, 16.6. Keto: 
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δ 202.9, 199.1, 186.3, 172.7, 167.7, 167.7, 156.3, 154.7, 153.9, 152.2, 150.1, 140.9, 139.2
, 137.6, 134.9, 132.4, 127.7, 122.2, 120.8, 118.3, 110.1, 108.8, 102.4, 68.0, 56.3, 32.4, 17.
1. ; IR (KBr, υ cm-1): 3419, 2926, 1607, 1468, 1288, 1021; HRMS (ESI) calcd. for 
C28H17O14 [M-H]-: 577.06238. Found: 577.06186. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
135 
 
 
M
O
M
Ot B
u
O
2
C
O
P
iv
O
O
M
e
C
O
2
M
e
O
M
e
1
3
7
136 
 
 
M
O
M
Ot B
u
O
2
C
O
P
iv
O
O
M
e
C
O
2
M
e
O
M
e
1
3
7
137 
 
M
O
M
Ot B
u
O
2
C
O
P
iv
O
O
M
e
C
O
2
M
e
O
M
e
1
3
7
138 
 
 
M
O
M
Ot B
u
O
2
C
O
P
iv
O
O
M
e
C
O
2
H
O
M
e
1
3
6
139 
 
 
M
O
M
Ot B
u
O
2
C
O
P
iv
O
O
M
e
C
O
2
H
O
M
e
1
3
6
140 
 
M
O
M
Ot B
u
O
2
C
O
P
iv
O
O
M
e
C
O
2
H
O
M
e
1
3
6
141 
 
 
142 
 
 
143 
 
144 
 
 
145 
 
 
146 
 
147 
 
 
148 
 
 
149 
 
150 
 
151 
 
 
152 
 
 
 
153 
 
Spectral Comparison. 
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Atom 
(Kumagai 
Numbering) 
Siegel  
13C 
(Enol) 
Siegel 
13C 
(Keto) 
Kumagai  
13C 
(Enol) 
Kumagai  
13C 
(Keto) 
Atom 
(Wrigley 
Numbering) 
Wrigley  
13C 
(Enol) 
Wrigley  
13C 
(Keto) 
12 202.6 202.9 202.7 202.9 13 202.4 202.5 
4’ 183.7 199.1 183.7 199.1 11 104.4 199.0 
9 172.7 186.3 172.8 186.3 4 182.8 186.1 
15 172.7 172.7 172.7 172.7 9 172.7 172.5 
9’ 167.5 167.7 167.5 167.6 5’-CO2H 167.5 167.4 
11 167.5 167.7 167.5 167.6 8-CO2H 167.4 167.4 
8’a 156.3 156.3 156.3 156.3 8’a 155.6 156.2 
7’ 154.5 154.7 154.5 154.5 7’ 154.5 154.5 
3 153.9 153.9 153.8 153.8 6 153.8 153.8 
10a 152.2 152.2 152.2 152.2 4a 151.6 152.1 
4a 150.2 150.1 150.2 150.1 10a 150.2 150.1 
2 140.8 140.9 140.7 140.8 7 140.7 140.8 
6 137.6 139.2 138.1 139.1 6’ 138.6 137.5 
6’ 132.4 137.6 137.6 137.6 2 138.2 139.1 
5 129.4 134.9 132.4 134.9 4 131.8 132.4 
7 128.3 132.4 129.9 132.4 3 129.8 134.9 
8 125.9 127.7 125.8 127.7 1 125.8 127.5 
5’ 120.7 122.2 120.6 122.2 5’ 121.6 122.2 
1 120.7 120.8 120.6 120.6 8 120.6 120.6 
155 
 
8a 118.7 118.3 118.5 118.2 9a 118.6 118.2 
4’a 110.1 110.1 110.1 110.1 8a 110.0 110.1 
9a 110.1 108.8 110.1 108.8 4’a 109.2 108.7 
3’ 104.4 56.3 104.2 56.2 8’ 102.8 102.4 
8’ 102.4 102.4 102.3 102.3 5 102.3 102.3 
4 102.4 102.4 102.3 102.3 2’ 65.8 66.9 
2’ 65.9 56.3 65.7 56.2 3’ N/D 56.2 
13 32.4 32.4 32.4 32.4 14 32.2 32.4 
14 16.6 17.1 16.5 17.0 12 16.4 16.9 
 
 
 
 
 
 
 
 
 
 
Atom 
(Kumagai 
Numbering) 
Siegel  
1H 
(Enol) 
Siegel  
1H 
(Keto) 
Kumagai 
1H 
(Enol) 
Kumagai 
1H 
(Keto) 
Atom 
(Wrigley 
Numbering) 
Wrigley 
1H 
(Enol) 
Wrigley 
1H 
(Keto) 
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15-OH 15.61 
(s, 1H) 
N/D N/D N/D N/D N/D N/D 
11,9’-OH 12.75 
(s, 2H) 
N/D 12.71 (s, 
2H) 
N/D 8,5’-OH N/D N/D 
2-OH 11.62 
(s, 1H) 
N/D 11.61 (s, 
1H) 
N/D 7-OH N/D N/D 
6’-OH 11.23 
(s, 1H) 
11.15 
(s, 1H) 
11.22 (s, 
1H) 
N/D 6’-OH N/D N/D 
3-OH 9.33 (s, 
1H) 
N/D 9.30 (s, 
1H) 
N/D 6-OH N/D N/D 
7’-OH 8.69 (s, 
1H) 
8.88 (s, 
1H) 
8.70 (s, 
1H) 
N/D 7-OH N/D N/D 
8 7.95 (s, 
1H) 
8.51 (s, 
1H) 
7.91 (s, 
1H) 
8.52 (s, 
1H) 
1 7.97 (s, 
1H) 
8.53 (s, 
1H) 
4 6.93 (s, 
1H) 
6.92 (s, 
1H) 
6.91 (s, 
1H) 
6.91 (s, 
1H) 
5 6.94 (s, 
1H) 
6.93 (s, 
1H) 
8’ 6.39 (s, 
1H) 
6.42 (s, 
1H) 
6.40 (s, 
1H) 
6.40 (s, 
1H) 
8’ 6.40 (s, 
1H) 
6.43 (s, 
1H) 
2’ 4.66 (s, 
2H) 
5.01 
(dd, J = 
8.1, 4.7 
Hz, 1H) 
4.71 
4.68 (s, 
2H) 
5.02 (dd, 
J = 11.6, 
9.2 Hz, 
1H) 
4.71 (dd, 
2’ 4.69 (s, 
2H) 
5.04 
(dd, J = 
9.0, 5.0 
Hz, 1H) 
4.73 
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(dd, J = 
11.3, 
4.2 Hz, 
1H) 
4.60 (m, 
1H) 
 
J = 11.6, 
4.9 Hz, 
1H) 
4.61 (dd, 
J = 11.6, 
9.2 Hz, 
1H) 
(dd, J = 
11.0, 
5.0 Hz, 
1H) 
4.64 
(dd, J = 
11.0, 
9.0 Hz, 
1H) 
13 2.70 (s, 
3H) 
2.67 (s, 
3H 
2.69 (s, 
3H) 
2.67 (s, 
3H) 
14 2.71 (s, 
3H) 
2.68 (s, 
3H) 
14 2.31 (s, 
3H) 
2.29 (s, 
3H) 
2.28 (s, 
3H) 
2.28 (s, 
3H) 
12 2.33 (s, 
3H) 
2.31 (s, 
3H) 
 
Table 2. Spectral comparison for Siegel, Wrigley, and Kumagai. 
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